What is the current stock price of Cellectar Biosciences, Inc. (CLRB)?

As of the latest market data, Cellectar Biosciences, Inc. (CLRB) is trading at $2.76. The stock has seen a loss of -2.13% today.

Does Cellectar Biosciences, Inc. (CLRB) pay a dividend?

Based on current data, Cellectar Biosciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Cellectar Biosciences, Inc.?

The current market capitalization of Cellectar Biosciences, Inc. (CLRB) is approximately unavailable.

CLRB

Cellectar Biosciences, Inc.·Healthcare

2.76

2.128%(−0.06)

Market Closed

3.30

19.565%(+0.54)

After Hours

Last Updated: — ET

52W L: $2.4352W H: $20.70

CLRB NEWS

seekingalpha.com

Mar 4

Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 4

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia

globenewswire.com

Feb 25

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time.

globenewswire.com

Feb 17

Cellectar Biosciences Expands Global Intellectual Property Estate

Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the European Medicines Agency (EMA) for Iopofosine I 131 as a Treatment for Waldenström Macroglobulinemia FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a broad expansion of its global intellectual property (IP) estate, including newly issued patents across Europe, Asia-Pacific, the Middle East, and the Americas.

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2005-11-10

Beta

0.40

Websitewww.cellectar.com↗